Document is current
Any future updates will be listed below
-
Authors
Kostka, Kristin
Roel, Elena
Trinh, Nhung T. H. https://orcid.org/0000-0003-2794-5322
Mercadé-Besora, Núria
Delmestri, Antonella https://orcid.org/0000-0003-0388-3403
Mateu, Lourdes
Paredes, Roger https://orcid.org/0000-0002-6553-691X
Duarte-Salles, Talita
Prieto-Alhambra, Daniel https://orcid.org/0000-0002-3950-6346
Català, Martí
Jödicke, Annika M.
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (COV-LT2-0006)
- License Information
-
More Information
Article History
Received: 4 March 2023
Accepted: 19 October 2023
First Online: 17 November 2023
Competing interests
: D.P.A.’s department has received grant/s from Amgen, Chiesi–Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. LM reports grants from Grifols, speaker fees from AstraZeneca and Gilead and participation in Advisory Boards for Gilead. NT is supported by the Norwegian Research Council (grant No. 288696) and has received internationalisation support from UiO: Life Science and travel grants from the Norwegian Research Council. The remaining authors declare no competing interests.
